2025
Preferences for Lisdexamfetamine vs Cognitive-Behavioral Therapy for Binge-Eating Disorder: Correlates and Outcomes.
Yurkow S, Ivezaj V, Pittman B, Grilo C. Preferences for Lisdexamfetamine vs Cognitive-Behavioral Therapy for Binge-Eating Disorder: Correlates and Outcomes. The Journal Of Clinical Psychiatry 2025, 86 PMID: 40338285, DOI: 10.4088/jcp.24m15552.Peer-Reviewed Original ResearchMeSH KeywordsAdultBinge-Eating DisorderCognitive Behavioral TherapyFemaleHumansLisdexamfetamine DimesylateMaleMiddle AgedPatient PreferenceTreatment OutcomeConceptsBinge-eating disorderTreatment preferencesModerate treatment outcomePatient treatment preferencesCognitive-behavioral therapyEffects of treatment preferenceTest main effectsCognitive-behavioralNo significant interaction effectsInteraction effectsBehavioral therapySignificant interaction effectCBTModerate outcomeEfficacious treatmentMain effectLisdexamfetamineTreatment outcomesParticipants' preferencesEffective interventionsEffects of treatmentDisordersRandomized controlled trialsNo preferenceLDXSafety of Stimulants Across Patient Populations
Oliva H, Prudente T, Mayerson T, Mignosa M, Oliva I, Potenza M, Jegede O, Angarita G. Safety of Stimulants Across Patient Populations. JAMA Network Open 2025, 8: e259492. PMID: 40343695, PMCID: PMC12065045, DOI: 10.1001/jamanetworkopen.2025.9492.Peer-Reviewed Original ResearchMeSH KeywordsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsHumansLisdexamfetamine DimesylateMethylphenidateRandomized Controlled Trials as TopicConceptsAttention-deficit/hyperactivity disorderRandomized clinical trialsAdverse eventsStimulant medicationData extractionSafety of stimulationRisk ratioIncreased riskMethodological quality assessmentPreferred Reporting ItemsPatient populationClinical conditionsDiverse patient populationsRisk of biasSafety of stimulant medicationsUnclear risk of biasTreatment of attention-deficit/hyperactivity disorderOverall AEsRandom-effects modelWeb of ScienceBinge eating disorderStimulant use disorderComprehensive literature searchMain OutcomesReporting Items
2015
New onset executive function difficulties at menopause: a possible role for lisdexamfetamine
Epperson CN, Shanmugan S, Kim DR, Mathews S, Czarkowski KA, Bradley J, Appleby DH, Iannelli C, Sammel MD, Brown TE. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology 2015, 232: 3091-3100. PMID: 26063677, PMCID: PMC4631394, DOI: 10.1007/s00213-015-3953-7.Peer-Reviewed Original ResearchConceptsBrown Attention-Deficit Disorder ScaleExecutive function difficultiesExecutive functionAttention Deficit Disorder ScaleLDX treatmentObjective cognitive functionMemory taskVerbal memoryVerbal recallCognitive measuresParagraph recallLifetime ADHDCognitive functionCognitive declineDisorder ScaleSubjective measuresMenopausal womenSubscale scoresLisdexamfetamineObjective measuresRecallEarly postmenopausal womenSystolic blood pressureCross-over studyHealthy menopausal women
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply